Nuevolution start trading of its shares on Nasdaq Stockholm main market
Stockholm, 25 June 2018 @ 09:00:00. “Tio, nio, åtta … tre, två, ett”, in this very moment, and with the sound of the bell, Nuevolution AB (publ) opened the financial markets in Stockholm and started trading of its shares (ticker: NUE) on Nasdaq Stockholm main market.
“Nuevolution was listed on Nasdaq Stockholm First North Premier on the 17th of December 2015. We identified the Premier segment of Nasdaq’s First North market as the optimal initial trading platform for the company. The IPO of Nuevolution in 2015 was a very important milestone for the company. It catalyzed the development of our drug candidate pipeline significantly, and under strict conditions and in a good and competitive environment, the First North Premier market place has trained us optimally in preparation for this day. In September 2017, we announced the intention to apply for the listing on the main market before end of first half of 2018, and today, we may pleasingly conclude, that it is the first day of trading on the main market for Nuevolution.”, said Alex Haahr Gouliaev, CEO of Nuevolution AB (Publ) and continued,
“This represents another major goal for the company. The listing on the main market only follows after a significant scrutiny of the company’s operations, evaluation of the company’s fitness and assessment of skills and experience of board and management. Being allowed for trading on the main market is an honor, and it represents a quality stamp, that will support our ambitious intentions for further growth and value creation, and as a main market company, now with a reach towards larger institutional and international investors also.
This is not an achievement by management alone. This is the result of a team effort of staff, management, board, advisors, but not the least and most importantly our many supportive shareholders and active investors without whom all of this would not have been possible!
On behalf of the board, management and staff of Nuevolution, we wish to express our sincere appreciation for the support that we receive on a daily basis from a strong and loyal investor base. The main market listing offers us even better conditions for long-term growth and value creation to the benefit of shareholders and the equally import aim, to discover better and safer treatment of cancer and severe inflammatory diseases. We are looking forward to continuing this joint team effort.”
For more information, please contact:
Alex Haahr Gouliaev, CEO
Phone: +45 3913 0902
Henrik Damkjær Simonsen, CFO
Phone: +45 3913 0947
Information about Nuevolution AB (publ)
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
The information was sent for publication, through the agency of the contact persons set out above, on Monday 25 June 2018, 09:00 CET.
Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com